Dr. Ali Chamseddine

Dr. Ali CHAMSEDDINE is a medical oncologist consultant from France with dual board certifications in medical oncology and clinical hematology, holding both MD and PhD degrees. Dr. CHAMSEDDINE acquired his expertise at the renowned Gustave Roussy Cancer Center in Villejuif, France, where he assumed the senior medical oncology consultant role. During his tenure, he played a pivotal role in consolidating and optimizing the operations of the International Oncology Department. Furthermore, Dr. CHAMSEDDINE completed a one-year post-doctoral fellowship at the Division of Cancer Medicine, Leukemia Department, at the prestigious MD Anderson Cancer Center in Houston, Texas, USA. His prolific research efforts have resulted in over 49 publications in distinguished journals, including a letter published in the prestigious New England Journal of Medicine. These publications have garnered 685 citations from reputable sources such as PubMed, Google Scholar, and the Web of Science Core Collection. As of January 2024, Dr. CHAMSEDDINE’s scholarly impact is reflected in an H-index of 12. Dr. CHAMSEDDINE’s clinical expertise spans the entire spectrum of oncology, primarily focusing on Precision Oncology, Gastrointestinal Tumors, Breast and Genitourinary Tumors, and Lung Cancer. He is a member of several esteemed professional organizations, including the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), and the European Hematology Association (EHA), among others.

Area of Interest

• Gastrointestinal cancers (Esophageal cancer, Gastric (stomach) cancer, Colorectal cancer, Pancreatic cancer, Liver cancer, Bile duct, Neuroendocrine and Carcinoid Tumors).
• Breast cancer.
• Genitourinary cancers (Prostate, Bladder, Kidney, Testicular, and Urethral).
• Lung cancer.
• Gynecologic cancers (cervical, ovarian, uterine, vaginal, and vulvar).
• Central nervous system (Brain) cancers.
• Soft-tissue sarcomas.
• Palliative and supportive care in cancer patients.
• Precision oncology with :
  –  The development of a patient-centric and personalized treatment approaches in cancer patients.
  –  The identification of predictive markers for a better benefit-risk balance of anticancer drugs.
  –  The implementation of liquid biopsy in cancer patients for a better molecular characterization of cancers for diagnosis, patient stratification to therapy, and longitudinal monitoring.

Nationality: French